Summary
Observability Phase 2 vision: Tool → Programme → Portfolio impact maturity model and central analytics capability beyond Looker Studio dashboards.
OS Hub 2026 Annual Platform goal
In 2026, Leadership teams use a shared Observability framework to make pipeline informed platform, tool and agent decisions, enabling disciplined prioritization and clear, external communication of the program impact of the platform
From: Lacking transparency and without a company wide definition of how, where, and to what degree our our platform tools impact the most consequential bottlenecks in drug discovery to inform how AI driven progress should be recognized, compared and acted upon across the pipeline
To: Establish a platform value framework and observability layer that makes the company’s strategic bets explicit: Which parts of the drug discovery process do we expect to bend first, what AI enabled improvement looks like in those areas, and how well we are accomplishing that strategy.
Milestones
Q1 | Q2 | Q3 | Q4 |
Platform pipeline and Tool program Observability have updated frameworks, with individual metrics for priority tools | 2 x quarterly leadership reviews of Platform pipeline and Tool-programme observability are both performed, driving decisions | 50% of priority tools have scientific impact captured and are available to leadership, across 50% of active programmes | Quarterly doubling of externally shared platform impact as insight requests can be delivered within 2 days from the existing data capture frameworks for major external presentations |
Metrics of success
80% of priority tools in Tool-programme impact have Scientific impact captured and available to leadership, across 80% of active pre-clinical programs and updated quarterly. Platform pipeline observability is comprehensively updated on a monthly basis
Made with Bullet